🔥 바이오 핫 테마 분석

S-Class [FHTX] Foghorn Therapeutics GAAP EPS of -$0.10 beats by $0.14, revenue of $16.1M beats by $8.17M

S-Class [RGNX] Regenxbio GAAP EPS of $0.43 beats by $0.42, revenue of $108.02M beats by $11.56M

S-Class [LLY] Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

S-Class [STOK] Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028

[TGTX] TG Therapeutics targets $890M-$905M 2026 U.S. BRIUMVI net revenue while anticipating subcutaneous Phase III results around year-end

[LLY] Eli Lilly’s olomorasib gets FDA breakthrough therapy status for pancreatic cancer

[MRNA] Moderna beats top-line and bottom-line estimates; reaffirms FY outlook